Q1 Earnings Estimate for TARS Issued By William Blair

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – William Blair issued their Q1 2026 earnings estimates for shares of Tarsus Pharmaceuticals in a research note issued on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown expects that the company will post earnings of ($0.06) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at $0.32 EPS, Q3 2026 earnings at $0.56 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $1.62 EPS.

Other analysts have also issued reports about the company. The Goldman Sachs Group raised their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research note on Wednesday. Guggenheim restated a “buy” rating and set a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Barclays cut their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $61.33.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock opened at $44.48 on Thursday. The firm has a market cap of $1.70 billion, a PE ratio of -11.67 and a beta of 1.01. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The business has a 50-day moving average price of $50.97 and a 200 day moving average price of $43.13.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million during the quarter, compared to analysts’ expectations of $58.80 million.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $25,000. GF Fund Management CO. LTD. purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at about $44,000. R Squared Ltd acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $53,000. Quarry LP purchased a new position in Tarsus Pharmaceuticals in the 4th quarter worth approximately $166,000. Finally, HighTower Advisors LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $207,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.